Last edition
News about "Gilead Sciences"
The European Commission has approved Trodelvy for first-line treatment of unresectable or metastatic triple-negative breast cancer, offering a new therapeutic option for patients with one of the most aggressive forms of breast cancer.
Gilead Sciences | 25/06/2026 | By News Bureau
US FDA Accepts Gilead's Once-Weekly Yeztugo for HIV Prevention
Gilead’s investigational once-weekly oral HIV prevention pill Yeztugo has been accepted for US FDA review, supported by strong clinical data showing high efficacy of lenacapavir in preventing HIV across 2 clinical trials. The therapy could become the first long-acting oral option for HIV prevention.
Gilead Sciences | 16/06/2026 | By News Bureau
Gilead and Merck Report Positive Phase 3 Results for Weekly HIV Pill
Gilead and Merck reported positive phase 3 results for the investigational once-weekly oral HIV therapy islatravir/lenacapavir, which has the potential to become the first approved long-acting weekly oral treatment for people living with HIV.
Gilead Sciences | 09/06/2026 | By News Bureau
Gilead Sciences Wins FDA Accelerated Approval for First HDV Treatment Hepcludex
Gilead Sciences receives Food and Drug Administration (FDA) accelerated approval for Hepcludex, the first and only approved treatment for chronic Hepatitis Delta Virus (HDV), addressing a major unmet need in severe viral hepatitis care.
Gilead Sciences | 26/05/2026 | By News Bureau
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
Gilead Sciences | 22/05/2026 | By News Bureau | 516
Gilead Sciences Completes Arcellx Inc. Acquisition Ahead of Anito-cel Launch
Under the terms of the transaction, Gilead acquired Arcellx for USD 115 per share in cash, plus one non?transferable Contingent Value Right (CVR) of USD 5 per share, representing a total implied equity value of approximately USD 7.8 billion at the time of closing.
Gilead Sciences | 29/04/2026 | By News Bureau | 105
Gilead Extends Tender Offer to Acquire Arcellx
Gilead extends tender offer to acquire Arcellx until April 24, 2026, providing additional time for shareholders to participate in the proposed acquisition.
Gilead Sciences | 02/04/2026 | By News Bureau | 140
Gilead and LEO Pharma to Advance Development of Oral STAT6 Program
STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signaling, which are clinically validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis, asthma, and COPD, amongst many others.
Gilead Sciences | 13/01/2025 | By Aishwarya | 278
PANTHERx Rare Collaborates with Gilead Sciences for Distribution of LIVDELZI
LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Gilead Sciences | 17/08/2024 | By Aishwarya | 326
A new paediatric drug center opened by Giliead Sciences
Development, clinical operations, legal / IP, medical affairs and regulatory teams will work together to create the company?s Global Paediatric Centre of Excellence, based in the North Dock area of the city centre.
Gilead Sciences | 12/04/2022 | By Sudeep Soparkar | 876
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy